文献速递类风湿关节炎

类风湿关节炎临床因素与滑膜细胞类型及状态的关联

Associations Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Types and States.
PubMed 文献 · Arthritis Rheumatol · 2024-01-19

在迄今最大规模同时具备临床与多细胞数据的队列中,研究纳入72例活动性类风湿关节炎患者,分析临床因素与滑膜细胞类型百分比及细胞类型丰度表型的关联;结果显示DAS28-CRP3较高与T细胞百分比更高相关,甲氨蝶呤且未用生物制剂者B细胞百分比高于未用改善病情抗风湿药者,多数使用生物制剂者归为内皮-成纤维细胞-髓系表型。

要点

  • DAS28-CRP3较高与滑膜T细胞百分比更高相关(P < 0.01)。
  • 接受甲氨蝶呤且未用生物制剂者B细胞百分比高于未用改善病情抗风湿药者(P < 0.01)。
  • 使用生物制剂者中57%归为内皮-成纤维细胞-髓系表型,无归为T细胞-成纤维细胞表型者。

核心结论

  • 在这项全面的临床因素筛选中,观察到改善病情抗风湿药与细胞表型存在差异关联,提示类风湿关节炎治疗可能比其他临床因素更影响滑膜细胞类型/状态并最终影响后续治疗反应。

研究设计与样本

  • 加速药物伙伴关系类风湿关节炎研究招募活动性类风湿关节炎患者,纳入未接受改善病情抗风湿药或对甲氨蝶呤或肿瘤坏死因子抑制剂应答不足者,系统收集临床因素,对炎症关节活检组织解离后行转录组与表位细胞索引测序,衍生细胞类型百分比与细胞类型丰度表型,分析临床因素与细胞类型百分比及细胞类型丰度表型的相关性。
  • 共研究72例患者,平均年龄57岁,75%为女性,83%血清阳性,平均类风湿关节炎病程6.6年,平均DAS28-CRP3评分4.8。

主要发现

  • DAS28-CRP3较高与T细胞百分比更高相关(P < 0.01)。
  • 接受甲氨蝶呤且未用生物制剂改善病情抗风湿药者B细胞百分比高于未用改善病情抗风湿药者(P < 0.01)。
  • 使用生物制剂改善病情抗风湿药者中57%归为内皮-成纤维细胞-髓系表型,无归为T细胞-成纤维细胞表型者。
  • 各细胞类型丰度表型在年龄、性别、类风湿关节炎病程或DAS28-CRP3方面无显著差异。

关键数值与推荐

  • 细胞类型丰度表型包括内皮-成纤维细胞-髓系、成纤维细胞、髓系、T与B细胞、T细胞与成纤维细胞、T与髓系细胞。
  • DAS28-CRP3较高与T细胞百分比更高相关(P < 0.01)。
  • 接受甲氨蝶呤且未用生物制剂改善病情抗风湿药者B细胞百分比高于未用改善病情抗风湿药者(P < 0.01)。
  • 使用生物制剂改善病情抗风湿药者中57%归为内皮-成纤维细胞-髓系表型,无归为T细胞-成纤维细胞表型者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recent studies have uncovered diverse cell types and states in the rheumatoid arthritis (RA) synovium; however, limited data exist correlating these findings with patient-level clinical information. Using the largest cohort to date with clinical and multicell data, we determined associations between RA clinical factors with cell types and states in the RA synovium. METHODS: The Accelerated Medicines Partnership Rheumatoid Arthritis study recruited patients with active RA who were not receiving disease-modifying antirheumatic drugs (DMARDs) or who had an inadequate response to methotrexate (MTX) or tumor necrosis factor inhibitors. RA clinical factors were systematically collected. Biopsies were performed on an inflamed joint, and tissue were disaggregated and processed with a cellular indexing of transcriptomes and epitopes sequencing pipeline from which the following cell type percentages and cell type abundance phenotypes (CTAPs) were derived: endothelial, fibroblast, and myeloid (EFM); fibroblasts; myeloid; T and B cells; T cells and fibroblasts (TF); and T and myeloid cells. Correlations were measured between RA clinical factors, cell type percentage, and CTAPs. RESULTS: We studied 72 patients (mean age 57 years, 75% women, 83% seropositive, mean RA duration 6.6 years, mean Disease Activity Score-28 C-reactive Protein 3 [DAS28-CRP3] score 4.8). Higher DAS28-CRP3 correlated with a higher T cell percentage (P < 0.01). Those receiving MTX and not a biologic DMARD (bDMARD) had a higher percentage of B cells versus those receiving no DMARDs (P < 0.01). Most of those receiving bDMARDs were categorized as EFM (57%), whereas none were TF. No significant difference was observed across CTAPs for age, sex, RA disease duration, or DAS28-CRP3. CONCLUSION: In this comprehensive screen of clinical factors, we observed differential associations between DMARDs and cell phenotypes, suggesting that RA therapies, more than other clinical factors, may impact cell type/state in the synovium and ultimately influence response to subsequent therapies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Weisenfeld D, Zhang F, Donlin L, et al. Associations Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Types and States. Arthritis Rheumatol. 2024. PMID: 37791989. doi:10.1002/art.42726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。